Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, P.O. Box 301402, Houston, TX, 77230-1402, USA.
Ann Surg Oncol. 2023 Oct;30(11):6325-6331. doi: 10.1245/s10434-023-13853-1. Epub 2023 Jul 26.
Advances in our understanding of melanoma biology and the role of immune checkpoint blockade and targeted therapy have ushered in a new and rapidly evolving era of multidisciplinary care for patients with melanoma. Based on efficacy for patients with metastatic melanoma, these systemic treatment approaches have been introduced into the adjuvant and, more recently, the neoadjuvant landscape. This report highlights the results of key clinical studies published or initially presented in 2021 that have informed our evidence-based approach to melanoma multidisciplinary care, primarily related to adjuvant and neoadjuvant approaches for patients with resectable or resected stage III or high-risk stage II melanoma and their impact on clinical care. Knowledge concerning these areas of active clinical investigation is critical for surgical oncologists who care for melanoma patients as the treatment landscape continues to evolve.
我们对黑色素瘤生物学的认识不断提高,免疫检查点阻断和靶向治疗的作用也不断增强,这为黑色素瘤患者的多学科治疗带来了一个崭新且快速发展的时代。基于转移性黑色素瘤患者的疗效,这些系统治疗方法已经被引入辅助治疗,最近也被引入新辅助治疗领域。本报告重点介绍了 2021 年发表或首次报告的关键临床研究结果,这些结果为我们提供了黑色素瘤多学科治疗的循证方法,主要涉及可切除或已切除 III 期或高危 II 期黑色素瘤患者的辅助和新辅助治疗方法,以及这些方法对临床治疗的影响。对于关注黑色素瘤患者的外科肿瘤医生来说,了解这些活跃的临床研究领域的知识至关重要,因为治疗领域还在不断发展。